Industry NewsFree Access

*Author for the correspondence: Tel.: +351 217 946 429 (ext. 14244); Fax +351 217 946 470;

E-mail Address: catarinareis@ff.ulisboa.pt

iMEDULisboa, Research Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal

IBEB, Biophysics & Biomedical Engineering, Faculty of Sciences, Universidade de Lisboa, Campo Grande, 1749-016, Lisboa, Portugal

Search for more papers by this author

Published Online:23 Apr 2018https://doi.org/10.4155/tde-2018-0003

Abstract

The present industry update covers the period 1–31 December 2017. Information was sourced primarily from scientific literature and various news websites, company press releases, regulatory and patent agencies. The most representative (not all) examples of research are herein described and they are mainly focused on metabolic diseases, cancer, blood pressure diseases, eyes diseases and, in some cases, in rare diseases. In this paper, there was a clear positive approval tendency for several companies where they offered novel therapeutic delivery candidates. Some patents related to the therapeutic field were also published during this month. Finally, the US FDA announced the availability of a draft guidance for industry for products containing nanomaterials (investigational, pre-market and post-market submissions).

Keywords:

References

1 Nanoparticles as a solution against antibiotic resistance? www.worldpharmanews.com/development/4234-nanoparticles-as-a-solution-against-antibiotic-resistance.Google Scholar
2 Makarewicz O, Klinger-Strobel M, Ernst J, Lautenschlaeger C, Pletz MW, Fischer D. A blue fluorescent labeling technique utilizing micro- and nanoparticles for tracking in LIVE/DEAD^® stained pathogenic biofilms of Staphylococcus aureus and Burkholderia cepacia. Int. J. Nanomedicine 11, 575 (2016).Crossref, Medline, Google Scholar
3 Nanoparticles help with malaria diagnosis – new rapid test in development - Fraunhofer ISC. www.isc.fraunhofer.de/en/press-releases/nanoparticles-help-with-malaria-diagnosis-new-rapid-test.htmlGoogle Scholar
4 Rangarajan S, Walsh L, Lester W et al. AAV5–Factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. NEJMoa1708483 377, 2519–2530 (2017).Crossref, Medline, CAS, Google Scholar
5 Silva CO, Martinho N, Aniceto N, Reis CP. Melanoma prevention: challenges and progresses in nanotechnology for melanoma prevention and treatment. In: CRC Concise Encyclopedia of Nanotechnology. Kharisov BI, Kharissova OV, Ortiz-Mendez U (Eds.), 453–465 (2016).Crossref, Google Scholar
6 White RM, Cech J, Ratanasirintrawoot S et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471(7339), 518–22 (2011).Crossref, Medline, CAS, Google Scholar
7 Hanson K, Robinson SR, Al-Yousuf K et al. The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. Oncotarget 9(3), 3815–3829 (2017).Medline, Google Scholar
8 Ebeid K, Meng X, Thiel KW et al. Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat. Nanotechnol. 13(1), 72–81 (2017).Crossref, Medline, Google Scholar
9 Rittchen S, Boyd A, Burns A et al. Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukemia inhibitory factor (LIF). Biomaterials 56, 78–85 (2015).Crossref, Medline, CAS, Google Scholar
10 Metcalfe SM, Muthukumarana PADS, Thompson HL, Haendel MA, Lyons GE. leukemia inhibitory factor (LIF) is functionally linked to axotrophin and both LIF and axotrophin are linked to regulatory immune tolerance. FEBS Lett. 579(3), 609–614 (2005).Crossref, Medline, CAS, Google Scholar
11 Faissner S, Mishra M, Kaushik DK et al. Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic. Nat. Commun. 8(1), 1990 (2017).Crossref, Medline, Google Scholar
12 Jung Y-J, Lee Y-T, Ngo VL et al. Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection. Sci. Rep. 7(1), 17360 (2017).Crossref, Medline, Google Scholar
13 Barini E, Miccoli A, Tinarelli F et al. The anthelmintic drug niclosamide and its analogues activate the Parkinson's disease associated protein kinase PINK1. ChemBioChem 19(5), 425–429 (2017).Crossref, Google Scholar
14 Kanter J, Kutlar A, Liles D et al. 613 Crizanlizumab 5.0 Mg/Kg increased the time to first on-treatment sickle cell pain crisis: a subgroup analysis of the Phase II sustain study. Blood 130(Suppl 1), 613 (2017).Google Scholar
15 US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer. www.worldpharmanews.com/astrazeneca/4235-us-fda-accepts-regulatory-submission-for-tagrisso-in-1st-line-egfr-mutated-non-small-cell-lung-cancer.Google Scholar
16 FDA approves first biosimilar for the treatment of certain breast and stomach cancers www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587378.htmGoogle Scholar
17 Ozempic^® (semaglutide) recommended for approval by the European regulatory authorities https://globenewswire.com/news-release/2017/12/15/1262717/0/en/Ozempic-semaglutide-recommended-for-approval-by-the-European-regulatory-authorities.htmlGoogle Scholar
18 Sunovion receives fda approval for lonhala™ magnair™ inhalation solution to treat copd http://news.sunovion.com/press-release/sunovion-receives-fda-approval-lonhala-magnair-inhalation-solution-treat-copdGoogle Scholar
19 FDA. Xepi (ozenoxacin): FDA approved drug products. (2017). www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208945Orig1s000TOC.cfm Google Scholar
20 FDA approves sanofi's admelog^® (insulin lispro injection) www.news.sanofi.us/2017-12-11-FDA-Approves-Sanofis-Admelog-R-insulin-lispro-injectionGoogle Scholar
21 GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US www.gsk.com/en-gb/media/press-releases/gsk-achieves-approval-for-nucala-mepolizumab-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-egpa-for-adults-in-the-us/Google Scholar
22 Wechsler ME, Akuthota P, Jayne D et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. 376, 1921–1932 (2017).Crossref, Medline, CAS, Google Scholar
23 FDA approves new pfizer biosimilar www.pfizer.com/news/press-release/press-release-detail/fda_approves_new_pfizer_biosimilarGoogle Scholar
24 Aerie pharmaceuticals announces U.S. FDA approval of rhopressa^® (netarsudil ophthalmic solution) 0.02% for the lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension www.businesswire.com/news/home/20171218006125/en/Aerie-Pharmaceuticals-Announces-U.S.-FDA-Approval-Rhopressa%C2%AEGoogle Scholar
25 FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM589467.htm?utm_campaign=12192017_PR_FDA+approves+first+gene+therapy+treatment&utm_medium=email&utm_source=EloquaGoogle Scholar
26 Dias MF, Joo K, Kemp JA et al. Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives. Prog. Retin. Eye Res. pii:S1350-9462(17), 30052–30056 (2017).Google Scholar
27 Garcia JM, Swerdloff R, Wang C et al. Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel vral stimulation test for the diagnosis of adult GH deficiency. J. Clin. Endocrinol. Metab. 98(6), 2422–2429 (2013).Crossref, Medline, CAS, Google Scholar
28 Aeterna zentaris announces FDA approval of macrilen (macimorelin) for diagnosis of adult growth hormone deficiency www.biospace.com/article/releases/aeterna-zentaris-announces-fda-approval-of-macrilen-macimorelin-for-diagnosis-of-adult-growth-hormone-deficiency/.Google Scholar
29 FDA approves drug to treat dangerously low blood pressure www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm590249.htmGoogle Scholar
30 European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer https://www.roche.com/media/store/releases/med-cor-2017-12-21.htmGoogle Scholar
31 Peters S, Camidge DR, Shaw AT et al. Alectinib versus crizotinib in untreated ALK -positive non–small-cell lung cancer. N. Engl. J. Med. 377(9), 829–838 (2017).Crossref, Medline, CAS, Google Scholar
32 Vedanta granted four U.S. patents for therapeutics based on beneficial gut bacteria https://ibdnewstoday.com/2017/12/15/vedanta-granted-patents-therapeutics-targeting-ibd-other-diseases/Google Scholar
33 BRIEF-India's lincoln pharmaceuticals gets patent for ‘antimalarial drug’ www.reuters.com/article/brief-indias-lincoln-pharmaceuticals-get/brief-indias-lincoln-pharmaceuticals-gets-patent-for-antimalarial-drug-idUSFWN1OI0THGoogle Scholar
34 US patent for therapeutic compositions patent (Patent # 9,833,428) https://patents.justia.com/patent/9833428Google Scholar
35 Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease https://patents.justia.com/patent/9845352Google Scholar
36 Drug products, including biological products, that contain nanomaterials - guidance for industry www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM588857.pdfGoogle Scholar
37 Roche and Ignyta reach definitive merger agreement www.roche.com/media/store/releases/med-cor-2017-12-22.htmGoogle Scholar
38 Boehringer ingelheim marks great progress in immuno-oncology research partnerships in 2017 www.boehringer-ingelheim.com/press-release/progress-immuno-oncology-partnerships-2017Google Scholar

Vol. 9, No. 5

Metrics
Downloaded 664 times

History

Received 5 January 2018

Accepted 12 March 2018

Published online 23 April 2018

Published in print May 2018

Information
© 2018 Newlands Press
Keywords
Financial & competing interest disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Loading ...

An industry update: what is the latest news in the therapeutic delivery field?

Abstract

References